Name: UMIN ID:
Unique ID issued by UMIN | UMIN000033794 |
---|---|
Receipt number | R000037955 |
Scientific Title | Phase II study of Nivolumab in patients with relapsed/refractory hematologic malignancies |
Date of disclosure of the study information | 2018/09/01 |
Last modified on | 2023/06/16 06:50:15 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/08/17 14:38:44 | ||
2 | Update | 2018/09/19 08:36:17 | Recruitment status |
|
3 | Update | 2018/10/05 11:00:26 | UMIN ID1 |
|
4 | Update | 2019/02/22 08:51:14 | Institutions |
|
5 | Update | 2020/03/18 11:32:35 | Key inclusion criteria Key inclusion criteria |
|
6 | Update | 2020/03/18 12:11:32 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Zip code Address Name of primary person or sponsor Institute Organization Nationality of Funding Organization Nationality of Funding Organization Address1 Organization Organization Address Address Tel Institutions |
|
7 | Update | 2020/03/18 12:15:34 | Date of IRB Last follow-up date |
|
8 | Update | 2023/06/16 06:50:15 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete |